ADCT - ADC Therapeutics amends Genmab deal to advance antibody-drug conjugate over finish line

Genmab A/S (GMAB) and ADC Therapeutics SA (ADCT) have amended their 2013 collaboration agreement related to continued development and commercialization of antibody-drug conjugate ((ADC)) camidanlumab tesirine (Cami).The revised contract eliminates the defined divestment process and allows ADCT to complete development, submit regulatory applications and advance the product into the marketplace. GMAB will convert its economic interest in Cami to tiered mid-to-high single-digit royalties on net sales.Cami combines GMAB's HuMax-TAC CD25-targeting antibody with ADCT's highly potent pyrrolobenzodiazepine warhead technology.Results from an early-stage study in last-line Hodgkin lymphoma patients showed an 86.5% response rate including a 48.6% complete response rate.A 100-subject Phase 2 trial is in process and will support a U.S. marketing application. Preliminary data should be available in H1 2021.GMAB down 1% premarket on light volume.

For further details see:

ADC Therapeutics amends Genmab deal to advance antibody-drug conjugate over finish line